当前位置: 首页 >> 检索结果
共有 7974 条符合本次的查询结果, 用时 2.8223373 秒

7601. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic.

作者: Megan L Ranney.;Valerie Griffeth.;Ashish K Jha.
来源: N Engl J Med. 2020年382卷18期e41页

7602. Novel Coronavirus and Old Lessons - Preparing the Health System for the Pandemic.

作者: John L Hick.;Paul D Biddinger.
来源: N Engl J Med. 2020年382卷20期e55页

7603. Regulating Vaping - Policies, Possibilities, and Perils.

作者: Jody L Sindelar.
来源: N Engl J Med. 2020年382卷20期e54页

7604. Fair Allocation of Scarce Medical Resources in the Time of Covid-19.

作者: Ezekiel J Emanuel.;Govind Persad.;Ross Upshur.;Beatriz Thome.;Michael Parker.;Aaron Glickman.;Cathy Zhang.;Connor Boyle.;Maxwell Smith.;James P Phillips.
来源: N Engl J Med. 2020年382卷21期2049-2055页

7605. The Toughest Triage - Allocating Ventilators in a Pandemic.

作者: Robert D Truog.;Christine Mitchell.;George Q Daley.
来源: N Engl J Med. 2020年382卷21期1973-1975页

7606. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.

作者: Frederick J Raal.;David Kallend.;Kausik K Ray.;Traci Turner.;Wolfgang Koenig.;R Scott Wright.;Peter L J Wijngaard.;Danielle Curcio.;Mark J Jaros.;Lawrence A Leiter.;John J P Kastelein.; .
来源: N Engl J Med. 2020年382卷16期1520-1530页
Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia.

7607. Covid-19 and the Stiff Upper Lip - The Pandemic Response in the United Kingdom.

作者: David J Hunter.
来源: N Engl J Med. 2020年382卷16期e31页

7608. Audio Interview: New Research on Possible Treatments for Covid-19.

作者: Eric J Rubin.;Lindsey R Baden.;Stephen Morrissey.
来源: N Engl J Med. 2020年382卷12期e30页

7609. Essential Thrombocythemia. Reply.

作者: Ayalew Tefferi.;Animesh Pardanani.
来源: N Engl J Med. 2020年382卷12期e21页

7610. Essential Thrombocythemia.

作者: Elisa Rumi.;Mario Cazzola.
来源: N Engl J Med. 2020年382卷12期e21页

7611. Essential Thrombocythemia.

作者: Roger A Fleischman.
来源: N Engl J Med. 2020年382卷12期e21页

7612. Community-wide Screening for Tuberculosis. Reply.

作者: Guy B Marks.;Nhung V Nguyen.;Greg J Fox.
来源: N Engl J Med. 2020年382卷12期1186页

7613. Community-wide Screening for Tuberculosis.

作者: Andrew D Kerkhoff.;Monde Muyoyeta.;Adithya Cattamanchi.
来源: N Engl J Med. 2020年382卷12期1185-1186页

7614. HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply.

作者: Amita Gupta.;Grace Montepiedra.;Gerhard Theron.
来源: N Engl J Med. 2020年382卷12期1184-1185页

7615. HIV, Pregnancy, and Isoniazid Preventive Therapy.

作者: Thierry Tiendrebeogo.;Xavier Anglaret.;Renaud Becquet.
来源: N Engl J Med. 2020年382卷12期1184页

7616. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Reply.

作者: Scott D Solomon.;John J V McMurray.; .
来源: N Engl J Med. 2020年382卷12期1182-1183页

7617. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

作者: Gavin A Lewis.;Erik B Schelbert.;Christopher A Miller.
来源: N Engl J Med. 2020年382卷12期1182页

7618. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

作者: Babak Yazdani.;Niklas Lutz.;Bernhard K Krämer.
来源: N Engl J Med. 2020年382卷12期1181-1182页

7619. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

作者: Rui Baptista.;Pedro Moraes-Sarmento.;Ricardo Fontes-Carvalho.
来源: N Engl J Med. 2020年382卷12期1181页

7620. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

作者: Kartik Gupta.;Navkaranbir S Bajaj.
来源: N Engl J Med. 2020年382卷12期1180-1181页
共有 7974 条符合本次的查询结果, 用时 2.8223373 秒